Windtree Therapeutics, Inc.

As of August 16, 2019, Windtree Therapeutics, Inc. is considered overvalued due to poor financial ratios, including a Price to Book Value of 0.18 and negative returns on capital and equity, indicating significant inefficiencies compared to its peers.

As of June 11, 2025, the market trend is mildly bearish, influenced by mixed signals: weekly indicators show some bullish momentum, while monthly indicators remain bearish, leading to an overall tempered bearish sentiment.

As of March 2022, Windtree Therapeutics, Inc.'s management team includes Mr. James Huang (Independent Chairman), Mr. Craig Fraser (President and CEO), and Dr. Pratap Paruchuru (Executive Director of Clinical Development), along with several independent directors on the Board.

Windtree Therapeutics, Inc. is a biotechnology company developing KL4 surfactant therapies for respiratory diseases, classified as a micro-cap with a market cap of $2.19 million and a recent net profit loss of $4 million. The company has no debt and does not pay dividends.

As of Jun 18, Windtree Therapeutics, Inc. has a market capitalization of 2.19 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -16.04 million over the latest four quarters. The company's shareholder's funds are 13.18 million, and total assets are 27.88 million as of Dec 24.